Realm Therapeutics (RLM) is advancing its pipeline to plan having received FDA approval to take its lead candidate PR022 a novel high concentration formulation of hypochlorous acid (HOCl), into Phase II studies in atopic dermatitis (AD). With a strong body of safety evidence on the active of PR022 at hand, RLM has effectively bypassed the Phase I stage. With a high unmet need for safer alternatives to standard topical corticosteroids in mild-tomoderate AD, RLM targets, alongside recently appr
01 Mar 2017
Leapfrogging Phase I in Atopic Dermatitis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Leapfrogging Phase I in Atopic Dermatitis
Realm Therapeutics (RLM:LON) | 0 0 0.3% | Mkt Cap: 57.1m
- Published:
01 Mar 2017 -
Author:
Emma Ulker -
Pages:
2
Realm Therapeutics (RLM) is advancing its pipeline to plan having received FDA approval to take its lead candidate PR022 a novel high concentration formulation of hypochlorous acid (HOCl), into Phase II studies in atopic dermatitis (AD). With a strong body of safety evidence on the active of PR022 at hand, RLM has effectively bypassed the Phase I stage. With a high unmet need for safer alternatives to standard topical corticosteroids in mild-tomoderate AD, RLM targets, alongside recently appr